PDGF receptor signaling networks in normal and cancer cells

Jean-Baptiste Demoulin; Ahmed Essaghir

doi:10.1016/j.cytogfr.2014.03.003

PDGF receptor signaling networks in normal and cancer cells

Cytokine Growth Factor Rev. 2014 Jun;25(3):273-83. doi: 10.1016/j.cytogfr.2014.03.003. Epub 2014 Mar 19.

Authors

Jean-Baptiste Demoulin¹, Ahmed Essaghir²

Affiliations

¹ De Duve Institute, Université catholique de Louvain, Brussels, Belgium. Electronic address: jb.demoulin@uclouvain.be.
² De Duve Institute, Université catholique de Louvain, Brussels, Belgium. Electronic address: ahmed.essaghir@uclouvain.be.

PMID: 24703957
DOI: 10.1016/j.cytogfr.2014.03.003

Abstract

For about four decades, platelet-derived growth factors (PDGF) and their receptors have been the subject of intense research, revealing their roles in embryo development and human diseases. Drugs such as imatinib, which selectively inhibit the tyrosine kinase activity of these receptors, have been approved for the treatment of cancers such as gastrointestinal stromal tumors and chronic eosinophilic leukemia. Today, the interest in these factors is still increasing in relationship with new potential clinical applications in cancer, stroke, fibrosis and infectious diseases. This review focuses on the mechanisms of PDGF receptor signaling, with an emphasis on pathways that are important for disease development. Of particular interest, recent studies revealed significant differences between normal and cancer cells regarding signal transduction by these growth factors.

Keywords: Myeloproliferative neoplasms; Oncogenes; PDGFRA; PDGFRB; Receptor tyrosine kinase.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Benzamides / therapeutic use
Fibrosis / drug therapy
Fibrosis / enzymology
Fibrosis / pathology
Gastrointestinal Stromal Tumors / drug therapy
Gastrointestinal Stromal Tumors / enzymology*
Gastrointestinal Stromal Tumors / pathology
Humans
Hypereosinophilic Syndrome / drug therapy
Hypereosinophilic Syndrome / enzymology*
Hypereosinophilic Syndrome / pathology
Imatinib Mesylate
Infections / drug therapy
Infections / enzymology
Infections / pathology
Leukemia
Piperazines / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors
Receptors, Platelet-Derived Growth Factor / metabolism*
Signal Transduction*
Stroke / drug therapy
Stroke / enzymology
Stroke / pathology

Substances

Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
Receptors, Platelet-Derived Growth Factor

Supplementary concepts

Pdgfra-Associated Chronic Eosinophilic Leukemia